National Eye Institute, National Institutes of Health, Bethesda, Maryland; and.
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland.
Retin Cases Brief Rep. 2024 Jul 1;18(4):512-516. doi: 10.1097/ICB.0000000000001425.
The purpose of this study was to report an unusual case of pseudoxanthoma elasticum presenting with an inflammatory phenotype associated with atypical and rapidly progressive subretinal fibrosis.
This was an observational case report.
A patient with a history of pseudoxanthoma elasticum presented with rapidly progressive subretinal fibrosis, particularly in the left eye, over the course of one year. The patient was noted at presentation to have intraocular inflammation, outer retinal attenuation, multifocal choroiditis-like lesions, and intraretinal fluid (in the absence of obvious clinical or angiographic signs of exudative choroidal neovascular membranes). An ocular inflammatory phenotype was diagnosed, and the patient was treated with a combination of local steroids and systemic corticosteroids/immunomodulatory agents. After initiation of these agents, the patient demonstrated functional and structural improvement, with partial outer retinal reconstitution, decreased intraretinal fluid, and lack of further progression of subretinal fibrosis.
This report describes an inflammatory phenotype of pseudoxanthoma elasticum associated with severe and atypical subretinal fibrosis. This case expands upon the currently known spectrum of inflammatory phenotypes associated with pseudoxanthoma elasticum. Treatment with corticosteroids or immunomodulatory treatment should be considered in similar cases.
本研究旨在报告一例罕见的伴有非典型、快速进展性的脉络膜视网膜下纤维化的假性黄色瘤弹性组织变性的炎症表型病例。
这是一项观察性病例报告。
一名假性黄色瘤弹性组织变性病史的患者在一年的时间内出现了快速进展性脉络膜视网膜下纤维化,左眼尤为明显。该患者在就诊时表现出眼内炎症、外层视网膜萎缩、多灶性脉络膜炎样病变和视网膜内液(无明显的渗出性脉络膜新生血管膜的临床或血管造影迹象)。诊断为眼部炎症表型,患者接受局部类固醇和全身皮质类固醇/免疫调节剂联合治疗。在开始使用这些药物后,患者的功能和结构得到改善,部分外层视网膜得到重建,视网膜内液减少,脉络膜视网膜下纤维化无进一步进展。
本报告描述了一例与严重非典型脉络膜视网膜下纤维化相关的假性黄色瘤弹性组织变性的炎症表型。该病例扩大了目前已知的假性黄色瘤弹性组织变性相关炎症表型谱。在类似病例中,应考虑使用皮质类固醇或免疫调节剂治疗。